Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
20 earlier
The expansion will create 400 jobs dedicated to making GLP-1 injectables across Resilience’s contract manufacturing facilities.
Original title: “Resilience and Lilly invest $750M to boost Cincinnati drug production”
AbbVie investors’ sky-high expectations led to a 4% share decline on Friday as the company reported more modest consensus beats than expected.
Original title: “AbbVie shares pressured as Q2 I&I beat falls below investor expectations”
Moderna’s norovirus vaccine failed in a Phase 3 trial, but the company still has faith in an ambitious revenue growth target thanks to ex-U.S. vaccine sales and a unanimous FDA adcomm win for mFLUSIVA.
Original title: “Moderna maintains 10% growth target despite Phase 3 norovirus miss”
Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.
Original title: “Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs”
Alnylam’s revenue cut “may create a near term credibility overhang and could “raise questions on peak sales potential, even if there’s tailwinds in the competitive landscape,” according to Stifel.
Original title: “Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise”
Deadline: 23-Nov-2026 The Clinical Cancer Research Programme supports clinical studies that aim to advance cancer treatment and improve outcomes for patients. The programme is offered by the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) and focuses on funding innovative ... Deadline: 23-Nov-2026 The Clinical Cancer Research Programme supports clinical studies that aim to advance cancer treatment and improve outcomes for patients. The programme is offered by the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) and focuses on funding innovative interventional clinical trials that have the potential to make a meaningful impact on cancer care. Support investigators conducting high-impact clinical trials. The programme focuses on three main research areas: ... Improving existing cancer treatments. Developing better treatment strategies. Optimizing therapies to improve patient outcomes. Supports investigator-led clinical cancer trials. Funds Phase I–III interventional studies. Provides USD 100,000 per year of trial duration. Focuses on therapy optimization, treatment burden, and early detection. The programme is offered by the Rising Tide Foundation for Clinical Cancer Research (RTFCCR) and focuses on funding innovative interventional clinical trials that have the potential to make a meaningful impact on cancer care. ... Improving cancer treatment approaches. Reducing the burden of disease and treatment.
Original title: “Apply for Clinical Cancer Research Funding Programme - fundsforNGOs”
The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.
Original title: “J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B”
Strong quarterly results are prompting Bristol Myers Squibb to lift its 2026 outlook, though the company is facing another delay for key Cobenfy Alzheimer’s data and a pushed-back readout for milvexian.
Original title: “BMS’ ‘big beat’ clouded by Cobenfy, heart disease data delays”
With Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.
Original title: “Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts”